Clift et al1 aimed to estimate prostate-specific antigen (PSA) contamination in the control arm of the CAP prostate cancer screening trial, concluding that there is ‘limited plausibility of deriving clear conclusions from trials of PSA screening’. However, their conclusion failed to acknowledge that the CAP intervention significantly increased prostate cancer detection: during the first 18 months following …